Status:
UNKNOWN
Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes
Lead Sponsor:
Lu Debin
Conditions:
Evidence of Liver Transplantation
Eligibility:
All Genders
10-40 years
Phase:
PHASE2
PHASE3
Brief Summary
Type 1 diabetes mellitus (T1DM)is characterized by the autoimmune destruction of the pancreatic β cells; as a result, patients with T1DM are dependent on exogenous insulin to control their blood gluco...
Detailed Description
Autologous transplantation of Bone marrow mesenchymal stem cells(approximately 2.5 x 106 cells/kg body weight) intravenously
Eligibility Criteria
Inclusion
- Ability to provide written informed consent from patients or Child guardian
- Confirmed diagnosis of type 1 diabetes by ADA criteria less than 18 weeks •
Exclusion
- Body Mass Index \>30
- Presence of acute stage as Active infection,recent myocardial infarction, recent cerebral vascular accident (CVA) or acute renal failure.
- Severe Organ damage(e.g. lung disease, or hematopoietic dysfunction, or liver dysfunction).
- Infectious diseases, e.g. HIV infection, or hepatitis B or C infection
- Presence of malignancy
Key Trial Info
Start Date :
July 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2014
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01157403
Start Date
July 1 2010
End Date
August 1 2014
Last Update
June 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Endocrine Department, the south west Hospital of the Third Military Medical University
Chongqing, Chongqing Municipality, China, 400038